ASTMH 2018

67th Annual Meeting

28 October – 1 November 2018
New Orleans, USA
Nathalie Strub-Wourgaft, NTD Director – presentation on fexinidazole in a symposium on sleeping sickness elimination
Colin Forsyth, Chagas Epidemiologist, Sergio Sosa Estani, Head of Chagas Clinical Programme, Eric Chatelain, Head of Drug Discovery Programme – symposium on screening and diagnosis of Chagas disease
Poster presentations on Chagas and onchocerciasis

COR-NTD Annual Meeting

26-27 October 2018 
New Orleans, South Africa
Sergio Sosa-Estani, Head of Chagas Clinical Program, and Andrea Marchiol, Chagas Access Project Manager – session on control and care of Chagas disease in health networks

DNDi announces new Director of Neglected Tropical Diseases

Former DNDi Medical Director Dr Nathalie Strub-Wourgaft takes over leadership of NTD programme

DNDi is pleased to announce the appointment of Dr Nathalie Strub-Wourgaft as the new Director of Neglected Tropical Diseases. She will assume her new role as NTD Director and member of DNDi’s Executive Team as of 1 July 2018.

MedTrop 2018

Congress of the Brazilian Society of Tropical Medicine

2-5 September 2018 
Recife, Brazil
Posters on advances and challenges for Chagas disease and an access project in Colombia
DNDi participating in several round tables on Chagas disease and cutaneous leishmaniasis and the satellite forum FSBEIN

DNDi agreement with Colombia Ministry of Health and Social Welfare to guarantee access to comprehensive care for Chagas patients

Bogotá, Colombia – 14 April 2018
Objective is to improve access to diagnosis and treatment of people affected by this disease
An agreement to facilitate and strengthen access to diagnosis and treatment of patients with Chagas and other diseases of public health interest has been signed by the Colombian Ministry of Health and Social Protection and the non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi).

Drug approved in Argentina for treatment of Chagas disease in children

Buenos Aires, Argentina – 13 April 2018
Argentina has approved the paediatric indication of a drug used for treatment of Chagas disease, benznidazole, which will now be available in 12.5 mg pills, the dose required to treat children under the age of 2. The indication was approved by the Argentinian National Administration for Drugs, Food, and Medical Technologies (ANMAT).